Nelson Advisors: Switzerland's MedTech Paradox: Record Growth, Fading Appeal
Switzerland's medical technology industry is having a strange kind of year. By almost every headline measure, it is thriving: output is expanding at twice the rate of the broader Swiss economy, exports are climbing, and research spending remains among the highest of any industrial sector in the country. Yet beneath those numbers, the people who run the country's medtech companies are sounding an alarm that has been building for several years and has now become impossible to ignore.
According to Swiss Medtech's 2026 sector study, the trade association representing the country's medical technology companies, Switzerland's long standing appeal as a place to invest, manufacture, and innovate in medtech is eroding, quietly, but unmistakably.
It is a paradox worth taking seriously, not just for the roughly 1,400 companies and 72,000 employees who make up the sector, but for a country whose economic identity has long rested on precision manufacturing, life sciences and a reputation for stability that global companies have historically been willing to pay a premium to access. If that premium is starting to look less worthwhile, the implications reach well beyond one industry.
A sector still outperforming the economy around it
Start with the good news, because there is real good news. Swiss medtech has grown at an average annual rate of 5.5% over the past two years, roughly double the growth rate of the Swiss economy as a whole.
The sector now accounts for close to 10% of Switzerland's industrial value added, exports around CHF 12 billion worth of goods annually, and generates a trade surplus of roughly CHF 5.5 billion, making it the third-largest contributor to the country's trade balance behind pharmaceuticals and watchmaking. Medtech companies reinvest around 12% of turnover into research and development, a ratio that puts the sector among the most research-intensive in the Swiss economy, comparable to segments of pharma and precision engineering.
There is also a quieter efficiency story hiding in the numbers. Swiss medtech products account for about 7.9% of the country's total medical expenditure, yet the cost of those products has risen only 1.9% in recent years, well below the 3.3% increase seen across healthcare spending more broadly. In an era when healthcare cost inflation is a political flashpoint in almost every developed country, that is not a small thing, it is evidence that the sector is delivering more clinical value per franc spent, not less.
By any conventional measure of industrial health, this looks like a sector firing on all cylinders. So why is Swiss Medtech, the industry's own trade body, using its flagship annual study to warn that the country is losing its edge?
The numbers hiding underneath the headline growth
The answer lies in a set of figures that sit uncomfortably next to the growth story. The first is jobs. Over the past decade, the Swiss medtech sector has typically added around 1,500 net new jobs a year, a steady, dependable engine of skilled employment in cantons from Bern to Zug. Over the past two years, that number has collapsed to just 200 net new jobs in total. Not 200 a year, 200 across the entire two-year period. A sector growing at 5.5% annually and adding almost no new employment is a sector that is either becoming dramatically more productive, moving its hiring elsewhere, or both. Swiss Medtech's data suggests it is largely the latter: companies are still growing revenue, but they are increasingly choosing to do the growing outside Switzerland.
The second warning sign is investment intent. In the latest survey, 43% of companies said they have no plans for new investment in Switzerland, the highest share since Swiss Medtech began tracking the question. That is not a marginal shift in sentiment; it is closer to half the industry effectively pausing on domestic capital deployment at a moment when the sector's own growth would, in an earlier era, have been expected to fuel expansion of factories, labs, and headcount at home.
The third is funding for the activities that have historically defined the sector's competitive advantage: production and R&D. Swiss Medtech's study points to a clear and continuing decline in the capital allocated to both. For an industry whose entire value proposition rests on precision manufacturing and research intensity, a pullback in exactly those two areas is arguably the most concerning signal of all, more so than any single quarter's growth or export number.
Layered on top of these figures is a broader sentiment shift. More than half of surveyed companies now rate Switzerland's attractiveness as a business location less favourably than they did five years ago. That is a remarkable reversal for a country that has spent decades positioning itself, successfully, as one of the most desirable places in the world to locate high value medtech operations, thanks to its regulatory credibility, skilled workforce, and proximity to both European and global markets.
Damian Müller, a member of Switzerland's Council of States and president of Swiss Medtech, framed the stakes plainly around the release of the study: the question the industry now faces is not whether medtech innovation has a future, but whether that future will still be located in Switzerland. Simon Michel, CEO of Ypsomed, one of the country's best-known medtech manufacturers, put it even more bluntly, noting that competing locations in the EU, China, and the United States have simply become more attractive than Switzerland for new investment decisions. When the CEO of a flagship national champion says that out loud, it tends to get noticed in Bern.
What is driving companies away, or at least giving them pause
It would be easy to assume a slowdown in a globally exposed, R&D intensive sector is simply about currency strength, interest rates, or the general chill that has settled over medtech and life sciences investment worldwide since 2022. Those macro pressures are real and Swiss Medtech does not pretend otherwise. But the study is notably specific about what companies themselves point to as the deciding factor: cost pressure combined with bureaucratic hurdles, rather than any loss of Swiss technical expertise or manufacturing quality.
That distinction matters. Switzerland is not losing companies because its engineers, regulatory scientists, or production quality have gotten worse, by most accounts they remain excellent. It is losing relative ground because the cost and complexity of doing business domestically have risen faster than the value companies get in return, at exactly the moment competitors have made themselves easier to work with.
Tellingly, the study notes that traditional Swiss medtech expertise, long the trump card in investment decisions, has not been the top-ranked investment criterion for companies since 2018. Cost and regulatory ease have overtaken it.
Nowhere is that regulatory friction more visible than in the tangled, half-decade saga of Switzerland's market access relationship with the European Union, which takes in roughly half of all Swiss medtech exports.
The regulatory backdrop: five years of friction with the EU
To understand why "bureaucracy" is not an abstract complaint but a specific, quantifiable cost for Swiss medtech companies, it helps to look at what happened to the Mutual Recognition Agreement (MRA) between Switzerland and the EU for medical devices.
The MRA effectively allowed Swiss certified devices to be treated as compliant in the EU market and vice versa. It lapsed in May 2021 after broader Swiss-EU institutional negotiations broke down, and Switzerland was overnight reclassified as a "third country" for medical device purposes. The practical consequences were immediate and expensive: Swiss manufacturers lost the ability to have their CE certifications recognised through Swiss notified bodies, were required to appoint a dedicated Authorised Representative inside the EU, had to register separately in the EU's EUDAMED database, and lost the vigilance and market-surveillance efficiencies that database access provides. For a sector that sends nearly half its output to the EU, this was not a paperwork inconvenience, it was a structural tax on every product launch and every regulatory update.
There has been real diplomatic movement to fix this. Following a broader Swiss-EU trade framework agreed in late 2024 and roughly two years of negotiation, an updated MRA was signed in March 2026, including a "dynamic alignment" mechanism designed to keep Swiss and EU device regulation automatically in step going forward, preventing a repeat of the 2021 rupture. That is genuinely good news, and it is the kind of outcome Swiss Medtech has been pushing for.
However, and this is the detail that matters for any company making an investment decision in 2026, the agreement is signed, not yet ratified. It still requires approval from the European Parliament and Council, and very likely a domestic referendum in Switzerland given how Swiss-EU treaties are typically handled. Realistic estimates put full implementation no earlier than late 2027. Until then, every one of the barriers introduced in 2021 remains in force: dual registration, EU representation requirements, and exclusion from EUDAMED all continue to add cost and delay for Swiss exporters, even as the political headlines suggest the problem has been "solved."
That gap between political resolution and operational reality is precisely the kind of unnecessary bureaucracy Swiss Medtech's leadership is calling out. It is also why the industry, in parallel, has been lobbying alongside its European counterpart, MedTech Europe, for a substantive revision of the EU's own Medical Device Regulation (MDR) and In Vitro Diagnostic Regulation (IVDR), rules widely criticised across the European medtech industry, not just in Switzerland, for imposing compliance costs that fall disproportionately on smaller manufacturers and slow the introduction of incremental device improvements that pose little safety risk. Swiss authorities have simultaneously pursued a parallel-track strategy of seeking formal recognition of FDA-approved devices, partly as a hedge against continued MDR/IVDR complexity and partly as leverage to encourage the EU itself to accelerate reform.
Seen against this backdrop, the 43% of Swiss medtech companies pausing investment and the collapse in job creation look less like a mysterious loss of confidence and more like a rational response to several years of regulatory limbo layered on top of already-high Swiss operating costs.
Where the growth is actually coming from
None of this means Swiss medtech has lost its capacity to innovate, quite the opposite. The sector study identifies artificial intelligence and digitisation as the areas of greatest growth potential going forward, alongside a broader industry shift toward integrated, patient centred solutions that combine devices, software, and data rather than selling standalone hardware. This is consistent with where global medtech investment has been heading for several years, and Swiss companies are not being left behind on the technology roadmap itself.
The catch is talent. Switzerland's study points to a shortage of AI and digital skills sufficient to meet this new direction of travel, and tellingly some companies are responding not by training locally but by building digital and AI teams abroad, in markets where that talent is more readily available. This is a subtler version of the same story playing out in jobs and investment more broadly: the work is still happening, the growth is still real, but an increasing share of it is happening somewhere other than Switzerland.
What Swiss Medtech is asking for
Given this diagnosis, Swiss Medtech's policy prescription is narrower and more targeted than a generic call for "more competitiveness." The association is explicitly asking the Swiss government and regulators for:
Systematic reduction of unnecessary domestic bureaucracy and administrative burden on medtech companies, rather than incremental or piecemeal fixes
Removal of trade barriers through ratification and implementation of international agreements, above all the updated EU MRA, so Swiss companies stop paying the ongoing cost of an already-agreed political fix that has not yet taken legal effect
Investment in digital and AI skills infrastructure domestically, so that the sector's own stated growth opportunity does not simply migrate to wherever the talent already exists
Continued advocacy, alongside European partners, for a more proportionate MDR/IVDR framework that does not penalise smaller and mid sized manufacturers disproportionately relative to the safety benefit gained
None of these asks are radical. They amount to a request that Switzerland stop making its own historic strengths, regulatory credibility, technical depth and a stable business environment, harder to access than they need to be. Swiss Medtech's framing is notably not defensive; it does not ask for protection from competition, subsidy, or special treatment. It asks, in effect, for the country to get out of its own way.
A sector of small companies, not just Ypsomed sized giants
It is worth remembering what the Swiss medtech landscape actually looks like beneath the handful of internationally recognisable names. The overwhelming majority of the sector's roughly 1,400 companies are small and medium-sized enterprises, many clustered in specialist regions such as the Bern-Solothurn-Jura "Medtech Alley," the Lake Geneva life sciences corridor around Vaud and Geneva, and the precision-manufacturing hubs of Ticino and central Switzerland. These firms rarely have in-house regulatory affairs departments the size of a large multinational's, nor the balance sheet flexibility to simply absorb a few years of dual EU-Switzerland registration costs while waiting for a treaty to be ratified.
That distinction helps explain why the aggregate growth figures and the aggregate warning signs can both be true at once. A relatively small number of larger, globally diversified manufacturers can continue growing revenue by leaning on capacity and regulatory infrastructure they have already built outside Switzerland, while a much larger number of smaller, domestically rooted suppliers, the companies that historically provided the bulk of the sector's steady job creation, are the ones most likely to freeze hiring, delay a planned facility upgrade, or quietly shift a product launch to an EU-based contract manufacturer instead. If that pattern continues, Switzerland risks hollowing out the very tier of the industry that gives it depth and resilience, even while headline export and turnover figures stay healthy for another few years.
Why this matters beyond one industry
It is tempting to read a sector study like this as a niche concern for an industry most people only think about when they need a hip implant or a glucose monitor. That would understate the significance. Medtech is Switzerland's third-largest trade surplus contributor, sits alongside pharma and finance as a pillar of the country's high-value export economy, and offers exactly the kind of skilled, well-paid, R&D-adjacent employment that most advanced economies are competing hard to attract and retain. A sector that can grow revenue at 5.5% a year while adding almost no net jobs and pulling back on capital investment is not a sector in crisis today, but it is a sector quietly relocating its future growth elsewhere, one investment decision at a time.
The MRA saga is instructive precisely because it shows how much of this erosion is self-inflicted or at least addressable through policy, rather than being an unavoidable consequence of global competition. A five year gap in mutual recognition, a signed but unratified fix, and a further eighteen month plus wait for implementation together represent roughly a lost half-decade during which Swiss exporters absorbed costs their competitors did not have to bear. That is not the kind of disadvantage that clever engineering or research intensity can fully offset.
Switzerland retains genuine, durable advantages in medtech: deep technical expertise, a dense cluster of suppliers and specialists, proximity to both European and global markets, and a regulatory reputation built over decades.
The 2026 sector study is best read not as a story of decline, but as a warning that those advantages are not self-sustaining. They have to be actively defended against a steady accumulation of avoidable friction, friction that competitor jurisdictions in the EU, the US, and increasingly China have been working systematically to reduce. Whether Switzerland treats this as an urgent policy priority, or as background noise beneath an otherwise reassuring growth headline, may determine which country captures the next decade of medtech investment that Swiss companies themselves are generating.
Nelson Advisors > European HealthTech, MedTech, Digital Health Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, MedTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies.www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, industry trends, deal commentary, market analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe's Leading Healthcare Technology Investment Banking Newsletter every week, join 5000+ HealthTech and MedTech subscribers today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards, corporates, venture capital and private investors to maximise shareholder value and investment returns.www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech#MedTech#DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #FemTech#ConsumerHealth #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA#Canada#Commonwealth#CorporateDivestitures #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments